KEY POINTS
- The White House issued a 100% tax on imported patented medicines.
- Firms can lower or eliminate taxes by building US factories.
- Most generic drugs remain unaffected by the new trade order.
President Donald Trump finalized a significant trade order on Thursday. The administration placed a 100% tariff on all patented drugs entering the country. This move seeks to enhance national security by increasing domestic pharmaceutical production.
Government officials believe the tax will force companies to move manufacturing to the US. The administration wants to reduce reliance on foreign supply chains for critical health products. Many industry experts view the policy as a strategic tool for negotiation.
The impact of the new levies might remain symbolic for now. Generic medicines are exempt from the heavy tax. These non-patented drugs represent the vast majority of prescriptions filled by American citizens.
Pharmaceutical companies have several ways to avoid paying the full tax. Firms that promise to open US plants by January 2029 will pay 20%. This rate can drop to zero if companies reach specific pricing agreements.
The government wants drug makers to offer lower prices to federal insurance programs. Past deals required firms to match prices found in major overseas markets. Several large corporations have already signed these agreements with the White House.
The White House expects more companies to negotiate in the coming weeks. Official statements claim the tariff threat has already triggered billions in planned investments. Small and medium businesses have 180 days to finalize their own deals.
Larger corporations have 120 days to coordinate with the administration. Some analysts worry that smaller firms may struggle with the new costs. Higher expenses for these businesses could eventually reach the consumer level.
The US will still honor existing trade deals with specific international partners. These allies include the United Kingdom, Japan, South Korea, and the European Union. These regions previously secured exemptions to keep their pharmaceutical tariffs at zero.
The UK government recently praised their specific partnership with the US. Under their deal, British patients may get faster access to new therapies. UK firms will continue to ship medicines to America without facing the new levies.
This policy is part of a broader effort to reshape American trade. The administration also adjusted tariffs on metals like steel and aluminum. They will stop taxing items that contain only small amounts of those materials.
Critics note that moving manufacturing to the US often increases operating costs. They argue that the final results of these policies depend on complex details. Most of the lower tariff rates are set to expire in early 2029.
